A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

… in Victoria, Australia. His clinical and translational research has identified new treatments, changed the standards … in Victoria, Australia. His clinical and translational research has identified new treatments, changed the standards …

As Air Quality Protections Weaken, Advocates Call on Healthcare Community to Consider Implications for Public Health, Patient Care

… has been classified by the International Agency for Research on Cancer as carcinogenic to humans. These particles … risk, and support environmental and climate health research. Safeguarding the atmosphere is not a peripheral …

Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

Should Biomarkers Be Used in the Clinical Management of ES-SCLC?

Challenges of Systemic Therapy for Patients with EGFR-mutated Lung Cancer After Progression on Targeted Therapy

… comparing outcomes of various treatment regimens in the search for the best-performing approach. … Challenges of …

Lung Cancer Screening in Brazil: Recent Efforts, Challenges, and Opportunities

… Researchers have demonstrated the need for, and benefits of, …

Keynote Address Explores the Future of Biomarkers in the ADC Era

… R. Hirsch outlined the current state of knowledge in ADC research, as well as what still needs to be learned. … Keynote …

Analysis Shows Cancer Death Rates Must Decline Faster to Reach ‘Moonshot’ Goal

… A team of NCI researchers recently investigated what needs to happen for the …

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

… Researchers evaluating the clinical significance of …

TIL Therapy Endures for Carefully Selected Patients: A Q&A with Dr. Benjamin C. Creelan

… Benjamin C. Creelan shares his passion for cell therapy research and insights into current data. … TIL Therapy Endures …

Asandeutertinib Goes Head-to-Head With Osimertinib in Phase II ESAONA Trial